• In June 2026, NeoGenomics finalized a civil settlement with the U.S. Department of Justice, agreeing to pay US$9,813,260 plus interest to resolve an investigation into consulting arrangements, having previously reserved US$11,200,000 for potential liabilities.
• Separately, the company launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for PTEN-deficient prostate adenocarcinoma, expanding its role in targeted prostate cancer care.
• We’ll now examine how closing the DOJ investigation, with settlement covered by existing reserves, may reshape NeoGenomics’ investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

NeoGenomics Investment Narrative Recap

To own NeoGenomics, you need to believe its focused oncology lab network and expanding test menu can eventually translate recurring volumes into sustainable profits despite ongoing losses. The DOJ settlement appears financially immaterial in the near term, given it was covered by existing reserves, but it underscores that compliance and legal exposure remain a live risk alongside execution on new product ramps like PanTracer and RaDaR.

The launch of PTEN IHC CDx, the first FDA approved IHC companion diagnostic for PTEN deficient prostate cancer, ties directly into NeoGenomics’ core catalyst: broader participation in personalized oncology testing. By integrating PTEN IHC CDx into NEO PanTracer Pro, the company is trying to deepen its presence in urologic oncology, where higher complexity testing could be an important offset to any future reimbursement or volume pressures elsewhere.

However, against this progress, the lingering legal and compliance risks that surfaced in the DOJ matter are something investors should be aware of, especially if...

NeoGenomics’ narrative projects $982.4 million revenue and $59.9 million earnings by 2029.

Uncover how NeoGenomics' forecasts yield a $15.06 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming NeoGenomics could reach about US$1.0 billion in revenue and US$12 million in earnings by 2029, which is far more upbeat than consensus and could look different once the DOJ settlement and related compliance questions are fully factored in.

Explore 2 other fair value estimates on NeoGenomics - why the stock might be worth just $15.06!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your NeoGenomics research is our analysis highlighting 1 important warning sign that could impact your investment decision.
• Our free NeoGenomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NeoGenomics' overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.